

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	To be assigned
Filing Date	July 30, 2003
First Named Inventor	Katia Vancompernelle
Group Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	2676-60451US

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	<i>Christa Z. Jorde</i>	Date Considered	8/8/04
-----------------------	-------------------------	--------------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number	To be assigned
Filing Date	July 30, 2003
First Named Inventor	Katia Vancornpernelle
Group Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	2676-604SIUS

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
CJ		Patent Abstracts of Japan, 1993, 1 page.
		GUY et al., Interleukin 1 and Tumor Necrosis Factor Activate Common Multiple Protein Kinases in Human Fibroblasts, The Journal of Biological Chemistry, 1991, pp. 14343-52, Vol. 266, No. 22.
		INOUE et al., Secual Response of Saccharomyces cerevisiae: Phosphorylation of Yeast Glyoxalase I by a Cell Extract of Mating Factor-Treated Cells, J. Biochem, 1990, pp. 4-6, Vol. 108.*
		KIM et al., Human Glyoxalase I, The Journal of Biological Chemistry, 1993, pp. 11217-21, Vol. 268, No. 15.
		RANGANATHAN et al., The Journal of Biological Chemistry, 1993, pp. 5661-67, Vol. 268, No. 8.
		SAKAMOTO et al., Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis, Blood, May 15, 2000, pp. 3214-18, Vol. 95, No. 10.
		THORNALLEY et al., Advances in glyoxalase research. Glyoxalase expression in malignancy, anti-proliferative effects of methylglyoxal, glyoxalase I inhibitor diesters and S-D-lactoylglutathione, and methylglyoxal-modified protein binding and endocytosis by the advanced glycation endproduct receptor, Critical Reviews in Oncology/Hematology, 1995, pp. 99-128, Vol. 20.
		VAN HERREWEGHE et al., Tumor necrosis factor-induced modulation of glyoxalase I activities through phosphorylation by PKA results in cell death and is accompanied by the formation of a specific methylglyoxal-derived AGE, Proceedings of the National Academy of Sciences of the United States, January 22, 2002, pp. 949-54, Vol. 99, No. 2.
		PCT International Search Report, PCT/EP02/01118, dated December 11, 2002.
		*Only page 4 of this article has been provided. The remainder will be provided as soon as possible.

Christina T. Vander

8/4/04

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.